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ABSTRACT 
Synthesis of a series of various 2, 5-disubstituted-1, 3, 4-oxadiazole derivatives (7a-7u) have been done. Synthesis of a series of intermediates 
(3a-3c and 5a-5c) have been also done, ethyl-2-phenoxyacetate (3a), ethyl 2-(2, 4-dichlorophenoxy)acetate (3b), ethyl 2-(4-nitrorophenoxy) 
acetate (3c), 2-phenoxyacetohydrazide (5a), 2-(2, 4-dichlorophenoxy) acetohydrazide (5b), 2-(4-nitrophenoxy)acetohydrazide (5c), and final 
product (7a-7u), 2-(phenoxymethyl)-5-phenyl-1, 3, 4-oxadiazole (7a), 4-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)aniline  (7b), 3-(5-
(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl) aniline (7c), 2-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)phenol (7d), 2, 4-dinitro-6-(5-
(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)phenol (7e), 2-(4-(methylthio)benzyl)-5-(phenoxymethyl)-1,3,4-oxadiazole (7f), 2-((2, 4-
dichlorophenoxy) methyl)-5-phenyl-1,3,4-oxadiazole (7g), 4-(5-((2, 4-dichlorophenoxy) methyl)-1,3,4-oxadiazol-2-yl)aniline (7h), 3-(5-((2, 4-
dichlorophenoxy) methyl)-1,3,4-oxadiazol-2-yl)aniline (7i), 2-(5-((2, 4-dichlorophenoxy) methyl)-1, 3, 4-oxadiazol-2-yl)phenol (7j), 2-(5-((2, 4-
dichlorophenoxy) methyl)-1,3,4-oxadiazol-2-yl)-4,6-dinitrophenol (7k), 2-((2,4-dichlorophenoxy) methyl)-5-(4-(methylthio)benzyl)-1,3,4-
oxadiazole (7l), (Z)-2-((2, 4-dichlorophenoxy) methyl)-5-styryl-1,3,4-oxadiazole (7m), (S)-4-(2-(5-((2,4-dichlorophenoxy) methyl)-1, 3, 4-
oxadiazol-2-yl)propyl)phenol (7n), 2-((4-nitrophenoxy) methyl)-5-phenyl-1, 3, 4-oxadiazole (7o), 4-(5-((4-nitrophenoxy)methyl)-1,3,4-
oxadiazol-2-yl)aniline (7p), 3-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-yl)aniline (7q), 2-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-
yl)phenol (7r), 2, 4-dinitro-6-(5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazol-2-yl)phenol (7s), 2-(4-(methylthio) benzyl)-5-((4-
nitrophenoxy)methyl)-1,3,4-oxadiazole (7t), (Z)-2-((4-nitrophenoxy)methyl)-5-styryl-1,3,4-oxadiazole (7u) and 5-((2, 4-
dichlorophenoxy)methyl)-1,3,4-oxadiazole-2-thiol (7v). 
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Infection: An infection is the detrimental colonization of a 
host organism by a foreign species. In an infection, the 
infecting organism seeks to utilize the host's resources to 
multiply, usually at the expense of the host.1 
Anti-infectives: Agents that are designed to kill, or prevent 
the growth of microorganisms without serious toxicity to the 
host.2 
Role of 1,3,4-Oxadiazole moiety in modern drug 
discovery. 
A Wide variety of substituted 1,3,4-oxadiazoles have 
attracted considerable attention in the field of drug 
discovery because of their wide range of pharmacological 
activities. Oxadiazoles have occupied a specific place in the 
field of medicinal chemistry due to its wide range of 
activities3. 
1,3,4-oxadiazole derivatives show anticonvulsant4, 
antimicrobial activity5, insecticide6, anti-tubercular activity7, 
anti-inflammatory activity8, cardiovascular activity9, 
antialzheimers activity10, anti-tumor agents11, antidiabetes12 
and spasmolytic activity13. 
A series of various derivatives of final products 2-
(phenoxymethyl)-5-phenyl-1, 3, 4-oxadiazole (7a), 4-(5-
(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)aniline  (7b), 3-(5-
(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl) aniline (7c), 2-(5-
(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)phenol (7d), 2, 4-
dinitro-6-(5-(phenoxymethyl)-1, 3, 4-oxadiazol-2-yl)phenol 
(7e), 2-(4-(methylthio)benzyl)-5-(phenoxymethyl)-1,3,4-
oxadiazole (7f), 2-((2, 4-dichlorophenoxy) methyl)-5-
phenyl-1,3,4-oxadiazole (7g), 4-(5-((2, 4-dichlorophenoxy) 
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methyl)-1,3,4-oxadiazol-2-yl)aniline (7h), 3-(5-((2, 4-
dichlorophenoxy) methyl)-1,3,4-oxadiazol-2-yl)aniline (7i), 
2-(5-((2, 4-dichlorophenoxy) methyl)-1, 3, 4-oxadiazol-2-
yl)phenol (7j), 2-(5-((2, 4-dichlorophenoxy) methyl)-1,3,4-
oxadiazol-2-yl)-4,6-dinitrophenol (7k), 2-((2,4-
dichlorophenoxy) methyl)-5-(4-(methylthio)benzyl)-1,3,4-
oxadiazole (7l), (Z)-2-((2, 4-dichlorophenoxy) methyl)-5-
styryl-1,3,4-oxadiazole (7m), (S)-4-(2-(5-((2,4-
dichlorophenoxy) methyl)-1, 3, 4-oxadiazol-2-
yl)propyl)phenol (7n), 2-((4-nitrophenoxy) methyl)-5-




yl)phenol (7r), 2, 4-dinitro-6-(5-((4-nitrophenoxy)methyl)-
1,3,4-oxadiazol-2-yl)phenol (7s), 2-(4-(methylthio) benzyl)-
5-((4-nitrophenoxy)methyl)-1,3,4-oxadiazole (7t), (Z)-2-((4-
nitrophenoxy)methyl)-5-styryl-1,3,4-oxadiazole (7u) and 5-
((2, 4-dichlorophenoxy)methyl)-1,3,4-oxadiazole-2-thiol 
(7v) has been synthesized by a mixture of equimolar 
amounts of the substituted 2-phenoxyacetohydrazide and 
substituted aromatic acid were, contained in a round bottom 
flask and suspended in 5 ml phosphoryl trichloride. The 
mixture was refluxed on a sand bath with vigorous stirring. 
The reaction was monitored by TLC. The reaction was 
continued till the substituted 2-phenoxyacetohydrazide was 
consumed completely. Initially, the color of reaction mixture 
was color less in case of phenol while in other phenols light 
yellow and reaction proceeded till reaction mixture became 
dark in color.  
All the compounds synthesized have been characterized by 
spectral data. 
2. Experimental 
2.1 General synthetic scheme for synthesis of 
substituted ethyl 2-phenoxyacetate (3a-3c)
 
 
Sr. No. Compound R 
1 3a -H 
2 3b Chloro group at position 1 and 4 




A mixture of equimolar amounts of the substituted phenol 
and ethylchloroacetate were, contained in a round bottom 
flask and suspended in 50-60 ml acetone and anhydrous 
potassium carbonate (1-2gm) was added in the mixture.   
The mixture was refluxed on a sand bath with vigorous 
stirring. The reaction was monitored by TLC. The reaction 
was continued till the substituted phenol was consumed 
completely. Initially, the colour of reaction mixture was color 
less in case of phenol while in other pheols light yellow and 
reaction proceeded till reaction mixture became dark in 
colour.  
Workup: The reaction mixture, when cooled, was filtered 
under vaccum to remove solid potassium carbonate and the 
filtrate thus obtained was evaporated under vaccum. The 
residue thus obtained was dissolved into ethylacetate (10-
15 ml) and washed with water twice. Ethylacetate layer was 
separated and dried over anhydrous sodium sulphate. The 
solvent was evaporated under vaccum and the residue 
(liquid product) thus obtained was used for next step. 
Yield %       :  96.56% (3a), 92.53% (3b), 90.97% (3c) 
TLC              : Silica gel G; Hexane: Ethyl acetate (8:2) 
                      Rf = 0.78 (3a), 0.79 (3b) and 0.56 (3c) 
IR (Spectrum 1) of (3a): 3020.32, 1732.94, 1595.22, 
1497.89, 1472.39, 1374.38, 1214.69, 1090.26, 1044.69, 
746.68, 696.42, 666.72cm-1 
IR (Spectrum 2) of (3b): 3094.58, 3020.30, 2985.44, 
1732.39, 1478.56, 1375.14, 1279.05, 1249.56, 1214.26, 
1105.25, 1046.92, 929.20, 854.11, 744.60 cm-1 
IR (Spectrum 3) of (3c): 3062.74, 3019.59, 1749.28, 
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2.2 General synthetic scheme for substituted 2-phenoxy acetohydrazide (5a-5c)    
 
 
              Figure 2:  
Sr. No. Compound R 
1 5a -H 
2 5b Chloro group at position 1 and 4 




A solution of substituted ethyl 2-phenoxyacetate (1 mol) and 
hydrazine hydrate (1.5 mol) were contained in a round 
bottom flask and suspended in 50-60 ml ethanol. The 
mixture was refluxed for 5-6 hr on a sand bath with vigorous 
stirring. The reaction was monitored by TLC. The reaction 
was continued till the substituted ethyl 2-phenoxyacetate 
was consumed completely. Initially, the color of reaction 
mixture was colour less in case of phenol while in other 
phenols light yellow and reaction proceeded till reaction 
mixture became dark in colour.  
Workup: The reaction mixture, when cooled, was filtered 
under vaccum to remove solid substituted 2-
phenoxyacetohydrazide. The solid thus obtained was 
washed with ethanol, dried and used for next step. 
Yield %             :  96.87% (5a), 77.75% (5b) and 95.58% (5c) 
Melting point : 100-105oC (5a), 150-155oC (5b) and 180-
185oC (5c) 
TLC                   : Silica gel G; Hexane: Ethyl acetate (1:1) 
                            Rf = 0.34 (5a), 0.59 (5b) and 0.47 (5c) 
IR (Spectrum 4) of (5a): 3357.51, 3291.45, 3274.32, 
2985.19, 1683.72, 1647.31, 1635.70, 1558.36, 1448.15, 
1418.67, 1362.37, 1119.37, 951.16, 741.62 cm-1 
IR (Spectrum 5) of (5b): 3315.48, 3259.87, 3226.55, 
3012.11, 1683.60, 1647.12, 1558.37, 1520.75, 1497.24, 
1456.97, 1387.27, 1245.18, 1138.64, 1046.29, 791.81 cm-1 
IR (Spectrum 6) of (5c): 3290.42, 3117.25, 3011.92, 
2946.03, 2868.98, 1653.19, 1540.35, 1490.22, 1418.99, 
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Sr. No. Compound R R 
1 7a -H -C6H5 
2 7b -H 4-NH2C6H5- 
3 7c -H 3-NH2C6H5- 
4 7d -H 2-OHC6H5- 
5 7e -H 2- OH-3,5-dinitroC6H5- 
6 7f -H 1-CH2-4-SCH3C6H5- 
7 7g Chloro at position 2 and 4 -C6H5 
8 7h Chloro at position 2 and 4 4-NH2C6H5- 
9 7i Chloro at position 2 and 4 3-NH2C6H5- 
10 7j Chloro at position 2 and 4 2-OHC6H5- 
11 7k Chloro at position 2 and 4 2- OH-3,5-dinitroC6H5- 
12 7l Chloro at position 2 and 4 1-CH2-4-SCH3C6H5- 
13 7m Chloro at position 2 and 4 C6H5CH=CH- 
14 7n Chloro at position 2 and 4 4-OHC6H5CH2(NH2)- 
15 7o Nitro group at position 4 -C6H5 
16 7p Nitro group at position 4 4-NH2C6H5- 
17 7q Nitro group at position 4 3-NH2C6H5- 
18 7r Nitro group at position 4 2-OHC6H5- 
19 7s Nitro group at position 4 2- OH-3,5-dinitroC6H5- 
20 7t Nitro group at position 4 1-CH2-4-SCH3C6H5- 
21 7u Nitro group at position 4 C6H5CH=CH- 
22 7v Chloro at position 2 and 4 -SH 
 
 
Sr. No. Compound PercentageYield Melting Point Rf Value 
1.  7a 78.95 95-100oC 0.78 
2.  7b 90.68 135-140oC 0.75 
3.  7c 89.44 155-160oC 0.66 
4.  7d 90.06 120-125oC 0.87 
5.  7e 91.66 105-110oC 0.70 
6.  7f 87.76 125-130oC 0.76 
7.  7g 85.29 115-120oC 0.69 
8.  7h 88.11 >250oC 0.75 
9.  7i 78.32 >250oC 0.75 
10.  7j 90.21 >250oC 0.75 
11.  7k 90.66 110-115oC 0.75 
12.  7l 79.63 >250oC 0.84 
13.  7m 97.30 >250oC 0.72 
14.  7n 78.39 140-145oC 0.74 
15.  7o 90.78 150-155oC 0.78 
16.  7p 89.19 100-105oC 0.44 
17.  7q 93.22 120-125oC 0.44 
18.  7r 91.89 >250oC 0.84 
19.  7s 92.67 >250oC 0.47 
20.  7t 92.90 >250oC 0.31 
21.  7u 94.12 >250oC 0.75 
22.  7v 88.98 120-125oC 0.78 
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Experimental Data 
IR (Spectrum 7) of (7a): 3011.86, 2977.55, 2966.99, 
1635.48, 1597.58, 1556.61, 1436.47, 1237.48, 1175.15, 
973.13, 771.21, 752.61 cm-1  
IR (Spectrum 8) of (7b): 3066.88, 3033.69, 2977.96, 
1662.08, 1540.49, 1496.42, 1172.78, 995.29, 896.02, 828.55 
cm-1 
IR (Spectrum 9) of (7c): 3110.94, 3077.17, 3020.98, 
1669.60, 1615.92, 1418.10, 1317.71, 1219.69, 1090.33, 
772.61 cm-1 
IR (Spectrum 10) of (7d): 3067.99, 3012.03, 2948.61, 
2890.45, 1652.29, 1540.77, 1456.56, 1219.55, 772.51, 
688.50 cm-1 
IR (Spectrum 11) of (7e): 3088.73, 3055.12, 3021.90, 
1598.93, 1540.10, 1489.26, 1338.88, 1219.60, 855.69, 
772.46 cm-1 
IR (Spectrum 12) of (7f): 2946.08, 2838.51, 1698.90, 
1635.69, 1496.90, 1473.30, 1362.27, 1216.53, 1136.47, 
843.65 cm-1 
IR (Spectrum 13) of (7g): 3094.58, 3020.30, 2985.44, 1732, 
1478, 1375, 1279, 1249, 1105, 929, 854, 744 cm-1 
IR (Spectrum 14) of (7h): 3344.56, 3274.44, 3024.34, 
2922.61, 1647.19, 1558.52, 1558.52, 1473.93, 1156.29, 
951.89, 798.86 cm-1 
IR (Spectrum 15) of (7i):  334.31, 3139.63, 1558.60, 
1520.61, 1464.99, 1295.24, 1204.84, 756.31 cm-1 
IR (Spectrum 16) of (7j): 3336.78, 2925.45, 2854.17, 
1652.45, 1624.40, 1540.76, 1474.58, 1435.42, 1388.64, 
1289.03, 1212.89, 1157.69, 1102.84, 1072.37, 799.08 cm-1 
IR (Spectrum 17) of (7k): 3087.57, 2921.42, 2872.32, 
2839.16, 1652.87, 1558.45, 1540.74, 1464.77, 1339.21, 
1219.56, 883.79, 772.31, 729.42 cm-1 
IR (Spectrum 18) of (7l): 3177.48, 3022.63, 2900.55, 
1601.85, 1525.74, 1474.15, 1391.16, 1226.00, 991.53, 
870.75, 793.81, 763.13 cm-1 
IR (Spectrum 19) of (7m): 2975.41, 2932.90, 1683.87, 
1647.21, 1558.45, 1533.57, 1507.23, 1448.15, 1219.86, 
773.05 cm-1 
IR (Spectrum 20) of (7n): 3446.78, 3013.35, 2976.92, 
2938.40, 1662.62, 1635.81, 1558.45, 1507.23, 1473.54, 
1219.90, 1084.93, 771.72 cm-1 
IR (Spectrum 21) of (7o): 3065.81, 3003.83, 2946.86, 
1698.96, 1669.97, 1647.22, 1558.41, 1520.83, 1473.33, 
1087.92, 940.84, 689.52 cm-1 
IR (Spectrum 22) of (7p): 3333.63, 3295.67, 3136.42, 
2907.44, 1635.61, 1591.39, 1508.27, 1340.76, 1251.21, 
1175.91, 1111.09, 844.68, 749.56 cm-1 
IR (Spectrum 23) of (7q): 3296.10, 3241.23, 3110.94, 
3077.03, 1590.12, 1507.54, 1435.99, 1339.53, 1250.66, 
843.50, 797.27 cm-1 
IR (Spectrum 24) of (7r): 3054.50, 2977.28, 2908.40, 
1516.22, 1340.38, 1251.29, 1220.74, 1064.25, 845.02, 
772.63 cm-1 
IR (Spectrum 25) of (7s): 3024.44, 2984.84, 1621.48, 
1539.88, 1456.63, 1374.18, 1339.92, 1286.23, 1063.36, 
865.57, 772.36 cm-1 
IR (Spectrum 26) of (7t): 3039.38, 2992.33, 1652.36, 
1623.35, 1558.08, 1475.23, 1220.67, 1129.95, 979.82, 
867.41, 772.58 cm-1  
IR (Spectrum 27) of (7u): 3088.29, 3054.22, 2992.16, 
1557.96, 1519.00, 1489.19, 1339.19, 1258.85, 1112.13, 
844.76 cm-1 
IR (Spectrum 28) of (7v):  3229.10, 3013.16, 2946.86, 
1698.96, 1669.97, 1647.22, 1558.41, 1520.83, 1473.33, 
1087.92, 940.84, 689.52 
3. Result and Discussion 
3.1 Characterization of Intermediate (3a-3c) 
IR:  The spectrum showed characteristic ester band in the 
range 1749-1720cm-1 and C-Cl stretching peak at in the 
range of 750-780 cm-1. The –OH stretching peak 
corresponding to the phenol in the range of 3450-3400cm-1 
was disappeared thus confirming formation of the desired 
intermediate. Also, the values are in agreement with those 
reported ethyl 2-phenoxyacetate.15 
3.2 Characterization of Intermediate (5a-5c) 
The spectrum showed characteristic hydrazide band in the 
range of 1640-1670cm-1 and the stretching peak 
corresponding to the ester in the range of 1725-11745cm-1 
was disappeared. N-H stretching band of –NH-NH2 group 
appeared in the range of 3325-3100cm-1. That it confirm the 
formation of the desired intermediate. Also, the values are in 
agreement with the reported 2-phenoxyacetohydrazide.15 
3.3 Characterization of 2, 5-disubstituted -1,3,4-
oxadiazole (7a-7u) 
 IR:  The spectrum showed characteristic absorption band 
accordingly of the presence of functional group. The Ar-C-H 
stretching showed the absorption band in the range of 3020-
3050 cm-1. The –C=N stretching band appeared in the range 
of 1630-1660 cm-1, -C=C- stretching peak comes in the range 
of 1400-1500 cm-1, alkyl C-H stretching peak comes in the 
range of 2800-2900 cm-1. Arylether stretching band 
appeared in the range of 1100-1200 cm-1. Compounds 7b, 
7c, 7h, 7i, 7n, 7p and 7q contain aromatic -NH2,  which 
showed N-H stretching band in the range of 3150-3300 cm-1 
3.4 Characterization of 5-((2,4-
dichlorophenoxy)methyl)--1,3,4-oxadiazole thiol (7v) 
IR :  In the solid state, the thiol (SH) form of the oxadiazole 
predominated the tautomeric thione (C=S). The 
characteristic SH stretching peak was seen 2550-2590 cm-
1.15
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